Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer

Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer

Novel oncology drugs often fail to progress from preclinical experiments to FDA approval. Therefore, determining which preclinical or clinical factors associate with drug activity could accelerate development of effective therapies. We investigated whether preclinical metrics and patient characteris...

Full description

Bibliographic Details
Main Authors: Brad Rybinski, H. Dean Hosgood, Sara L. Wiener, Daniel A. Weiser
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
targeted therapy
mouse model
patient derived (tumor) xenograft model
co-clinical trials
non-small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.587377/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.587377/full

Similar Items